Omega-3 for Depression and Other Cardiac Risk Factors - 2
Status:
Completed
Trial end date:
2018-09-13
Target enrollment:
Participant gender:
Summary
The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to
determine whether antidepressant augmentation with two grams of EPA omega-3 per day is
superior to antidepressant therapy alone for major depression in patients with coronary heart
disease (CHD).